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Herpesviruses encode a unique serine protease essential for viral capsid maturation. This protease under-
goes autoprocessing at two sites, R and M, at the consensus sequence (V, L, I)P3-XP2-AP1/SP1 (where X is a
polar amino acid). We observed complete autoprocessing at the R and M sites of Marek’s disease virus (MDV)
protease following production of the polyprotein in Escherichia coli. Site-directed mutagenesis confirmed the
predicted sequence of the R and M sites, with the M site sequence being nonconsensual: MP3-NP2-AP1/SP1.
Mutagenesis and expression kinetics studies suggested that the atypical MDV M site was cleaved exclusively
by the processed short protease, a feature making MDV unique among herpesviruses.
Marek’s disease virus (MDV), the causative agent of a type of
T lymphoma in chickens, is a herpesvirus classified as gallid her-
pesvirus 2 in the Mardivirus genus of the Alphaherpesvirinae sub-
family. Marek’s disease is one of the most important and wide-
spread infectious diseases of chickens, despite the availability of
antitumor vaccines (11).
As with other herpesviruses, MDV virions contain multiple
layers, which are assembled in several stages. The spherical pre-
cursor capsid, the procapsid, consists of four proteins surrounding
an internal scaffold. It forms a major, transient intermediate in the
capsid maturation pathway in vivo (14). The scaffold is composed
of the products of two overlapping genes (UL26 and UL26-5 in
herpes simplex virus type 1) encoding proteins with identical C
termini. The N-terminal part of UL26 corresponds to one of the
two proteases produced by herpesviruses. During capsid matura-
tion, the UL26-encoded protease precursor undergoes autopro-
cessing, releasing the N-terminal protease domain by cleavage at
the R site. This domain undergoes further autoprocessing and
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TABLE 1. Primers used for pET construction
Primer Sequence (5–3) Directiona Construct
862 CCATGGATCCGGCCGACCATCCATCGGTG F pET-8B6
863 CTCGAGTGCTTGCAAATACTTTTGTCCAG R pET-8B6
864 GGATCCGATGAACACTCAATCTTCTCGCCC F pET-FD6
865 CTCGAGAGCATTCATGGTATCCCGTG R pET-FD6
904 GCTCTAGATCATGATGAATCCGGCCGACCATCC F pET-UL26
905 GCTCTAGACTCGAGTTATTGATGCGCCATCATTTG R pET-UL26
T7 TTAATACGACTCACTATA Fm S116D A234R L232M
859 GAATTCTGGACGGTTCTATTAGCGATTGC Rm S116D A234R L232M
914 TCCCCCGGTGCTAGGCGTCGTGAGGACAGGTCGACCGATGGAAGATAATT IR S116D
913 TATATATAATTACAAATTATCTTCCATCGGTCGACCTGTCCTCACGACGC IF S116D
910 GTCATTGAATCGGTCAATGCCGTAAAAGAAGATCTTTGCAAATACTTTTG IR A234R
909 CTGGTATAACTGGACAAAAGTATTTGCAAAGATCTTCTTTTACGGCATTG IF A234R
M200 CCGTAAAAGATGATGCTTGCAACATCTTTTGTCC IR L232M
M199 GGTATAACTGGACAAAAGATGTTGCAAGCATC IF L232M
902 GACCTTGCTATCACAGGG Fm A638R M636V
905 GCTCTAGACTCGAGTTATTGATGCGCCATCATTTG Rm A638R M636V Sc
912 TCACTGGTGCGGTGTATACCAGCTACGGCAGATCTATTCATGGTATCCCG IR A638R
911 GCATCGAGCAATCACGGGATACCATGAATAGATCTGCCGTAGCTGGTATA IF A638R
M102 TGGTGCGGTGTATACCAGCTACGGCGCTAGCGTTAACGGTATCCCGTGAT IR M636V
M101 GCATCGAGCAATCACGGGATACCGTTAACGCTAGCGCCGTAGCTGGTATA IF M636V
M122 TCATGAATGTCATCTTTTACGGCATTGACCGA Fm Sc
a F and R, forward and reverse primers, respectively; IF and IR, internal forward and internal reverse primers, respectively, used for overlapping PCR to introduce













then cleaves the UL26-5-encoded protein at an additional site
(M), near the C terminus, releasing a 25-amino-acid peptide that
tethers the scaffold to the capsid shell. This step coincides with
genome packaging; it is the final step in capsid maturation and is
therefore a key stage in capsid assembly (21).
The herpesvirus protease, which belongs to a new class of
serine proteases with a specific Ser-His-His catalytic triad (18),
is highly conserved (up to 90%) among members of one her-
pesvirus subfamily (12). A naturally occurring cleavage se-
quence has been identified for the R and M sites: (V, L,
I)-X-A/S, where X is a polar amino acid.
The catalytic triad (His49-Ser116-His135) and the cleavage
FIG. 1. Comparison of autoprocessing of the wild-type MDV protease precursor and that of precursors with mutations affecting the catalytic
and cleavage sites (R and M). (A) Schematic representation of the protease polyprotein, with its R and M cleavage sites indicated. Hatched and
gray boxes indicate the protease part of the protein and the matured scaffold protein, respectively. A part of the amino acid sequences of all
constructs, with each mutation being framed by a rectangle, is indicated below the scheme. (B) Diagram of cleavage products, with their calculated
molecular masses shown. (C) Western blots of proteins corresponding to the constructs expressed in E. coli 3 h after induction (with 1 mM IPTG
[isopropyl--D-thiogalactopyranoside]). Two blots, corresponding to the same sodium dodecyl sulfate-polyacrylamide gel (1), were probed with the
antiprotease MAb 8B6 (left) and the anti-scaffold protein MAb FD6 (right). The molecular mass of the marker and that of the immunodetected
polypeptide are indicated to the right and the left of each blot, respectively. ns, nonspecific band from E. coli; Ctrl, negative control (E. coli).
(D) Kinetics of hydrolysis of wtPP. Samples of the wtPP expressed in E. coli were collected at various times after induction with 1 mM IPTG and
analyzed by Western blotting. (Left) Analysis of five time points of the kinetic assay. The blot was probed with the antiprotease MAb 8B6. (Right)
Analysis of three time points of the kinetic assay. The blot was probed with the anti-scaffold protein FD6.












sites R (232-LP3-QP2-AP1/SP1-235) and M (636-MP3-NP2-AP1/
SP1-639) were identified by aligning the predicted amino acid
sequence of the polyprotein of MDV with the analogous
polyproteins of alphaherpesviruses. Surprisingly, the predicted
M site does not match the consensus sequence, differing at
MP3. We characterized the MDV protease cleavage sites by
production of the wild-type polyprotein (wtPP) of MDV RB1B
and a series of mutants with modified catalytic and cleavage
sites by use of a pET-14 expression system (Novagen).
The wtPP gene was amplified by PCR using the primers
listed in Table 1 and the PBS library, as previously described
(8). It was inserted into the appropriate restriction sites of
pET-14 to generate pET-UL26, which was used as a tem-
plate for PCR mutagenesis and as a subcloning vector for
mutated DNA fragments. Mutations were introduced at ap-
propriate locations, employing the overlapping PCR tech-
nique (6) with the primers listed in Table 1. Western blot
immunodetection of the proteins was carried out with
monoclonal antibodies (MAb) against the protease (8B6)
and the scaffold protein (FD6) by use of a passive blotting
protocol that allows the analysis of two identical symmetri-
cal immunoblots (1). MAb were produced as previously
described (15), using His-Bind resin-purified polypeptides
produced in the pET-22 system (Novagen) (Table 1) as an
antigen.
We assessed the ability of the MDV polyprotein to undergo
autoprocessing in Escherichia coli by comparing the MDV
wtPP with an S116D mutant harboring mutations in the active
site of the enzyme, predicted to result in an absence of catalytic
activity (4, 17, 19) (Fig. 1A). As expected, no cleavable product
was detected with the S116D mutant; this is consistent with an
absence of processing at the R and M sites (Fig. 1B and C). By
contrast, with the wtPP, products, most likely cleaved at R,
were detected with the antiprotease MAb 8B6 or the anti-
scaffold protein MAb FD6.The comparison between the prod-
ucts of cleavage revealed by FD6 and the Sc control (where Sc
represents construction of the scaffold protein from the pre-
dicted R to the carboxyl end) seems to indicate that the prod-
uct of scaffolding could correspond to a total cleavage on the
level of the predicted sites R and M, considering the observed
shift of migration between the wild type and the Sc control
(predicted carboxyl fragment of 2,655 Da removed). Autopro-
cessing of the MDV polyprotein seems to occur in the E. coli
expression system, which is consistent with findings for other
herpesviruses (Fig. 1B and C) (3, 16).
To confirm the positions of the predicted R and M cleavage
sites, we generated two mutants, the A234R and A638R mu-
tants. As with the wtPP, R cleavage products were immuno-
detected for the A638R mutant (Fig. 1C). Two different scaf-
fold peptides were detected for the wtPP and the A638R
mutant, possibly corresponding to scaffold proteins cleaved in
M and not cleaved at M, respectively (Fig. 1B), and compari-
son of the A638R mutant with the scaffold control seems to
confirm this. These results are therefore consistent with the
predicted site acting as a genuine atypical M site.
The Western blot profile obtained with the A234R mutant
was identical to that for the S116D mutant, with one immuno-
reactive band of 75 kDa (Fig. 1B and C). Surprisingly, no
polyprotein cleaved at M (72-kDa band) was detected, whereas
such polyproteins are generally detected with other herpesvi-
ruses (Fig. 1B) (5, 7, 8, 9, 16, 19).
We therefore carried out liquid chromatography-mass spec-
trometry experiments to confirm the peptide profiles obtained.
Protein bands were excised manually from electrophoresis gels
stained with Coomassie blue, subsequently reduced and alkylated,
and finally subjected to in-gel proteolysis with trypsin or Lys-C.
All digested proteins were sequenced by nano-liquid chromatog-
raphy–tandem mass spectrometry (Q-TOF-Ultima Global equipped
with a nano-electrospray ionization source, coupled with Cap
LC nanoHPLC; Waters Micromass). Data were interpreted
using ProteinLynx global server software (Waters Micromass).
All immunoreactive polypeptides were clearly identifiable,
with a coverage of 5 to 73% (Table 2), confirming our identi-
fication of the R and M sites. We also confirmed that the
75-kDa product corresponds to the uncleaved protein. Thus,
MDV seems to differ from other herpesviruses in that invali-
dation of the R site prevents cleavage of the M site, indicating







(%) C-terminal end of polypeptide
a
wtPP 30 Trypsin 12 73 223-MAGITGQKYLQA-234
55 Lys-C 3 5 627-ESIEQSRDTMNA-639
A638R mutant 30 Trypsin 10 63 223-MAGITGQKYLQA-234
57 Trypsin 4 12 646-TSDAGVDVFINQMMAHQ-663
S116D mutant 75 Trypsin 9 24 646-TSDAGVDVFINQMMAHQ-663
A234R mutant 75 Trypsin 15 27 646-TSDAGVDVFINQMMAHQ-663
A234R M636V mutant 75 Trypsin 8 15 646-TSDAGVDVFINQMMAHQ-663
72 Lys-C 4 7 627-ESIEQSRDTVNA-639
L232M mutant 75 Trypsin 17 29 646-TSDAGVDVFINQMMAHQ-663
M636V mutant 30 NDb ND ND ND
55 ND ND ND ND
a Underlining represents the catalytic site R or M cleaved after P1. Numbers indicate amino acid residues.
b ND, not determined.












that the MDV M site may be cleaved exclusively by the pro-
cessed short protease domain.
To confirm this hypothesis, we carried out a kinetic study with
the wtPP construct, collecting protein lysate samples at various
times after induction (Fig. 1D). The R site was rapidly cleaved, as
both the processed short protease and the scaffold protein were
detectable 3 min after induction. While the 75-kDa uncleaved
polyprotein was immunodetected in all samples, the 72-kDa
polyprotein cleaved at M was not detectable until 2 h after induc-
tion. Given the strong signal seen at this time in the immunoblot
revealed by 8B6, a high concentration of processed short protease
seems to be necessary for cleavage of the M site of the polypro-
tein. However, scaffold protein cleavage in M occurs early (i.e., 3
min postinduction), demonstrating a very rapid cleavage of the M
site of this processed substrate.
The lack of M site cleavage when the R site was not cleav-
able may be due to insufficient recognition of the atypical
MDV M site by the full-length protease. We tested this hy-
pothesis by replacing the nonconsensual MP3 in the MDV M
site with the consensual VP3 of other alphaherpesviruses. First,
we confirmed that this modified MDV M site was fully cleaved
in the M636V mutant (Fig. 2), demonstrating that the M636V
substitution did not prevent M cleavage. We then introduced
the M636V mutation into the mutant with the invalidated R
site (the A234R mutant) to generate the A234R M636V mu-
tant. Two bands, at 75 kDa and 72 kDa, were detected on
FIG. 2. Mutation of the P3 amino acid of cleavage sites R and M of the MDV protease precursor. (A) Schematic representation of the protease
polyprotein, with its R and M cleavage sites indicated. Hatched and gray boxes indicate the protease part of the protein and the matured scaffold
protein, respectively. A part of the amino acid sequences of all constructs, with each mutation being framed by a rectangle, is indicated below
the scheme. (B) Diagram of cleavage products, with their calculated molecular masses shown. (C) Western blots of proteins corresponding
to the constructs expressed in E. coli 3 h after induction (with 1 mM IPTG [isopropyl--D-thiogalactopyranoside]). The blot was probed with
the anti-scaffold protein MAb FD6. The molecular mass of the marker and that of the immunodetected polypeptide are indicated to the right
and the left of the blot, respectively.












Western blots, suggesting that both the full-length precursor
and the polyprotein cleaved at the M site were present, as
confirmed by mass spectrometry (Table 2; Fig. 2). Thus, the M
site was recognized by the full-length protease once the me-
thionine at P3 had been replaced with a valine residue, con-
firming the importance of the P3 position in the herpesvirus
cleavage site, as demonstrated in previous studies for herpes
simplex virus type 1 (9, 10) and cytomegalovirus (13, 19).
We further investigated the impact of having a methionine
residue in the P3 position by introducing MP3 in the R site (the
L232M mutant). Similar Western blot results were obtained
for the S116D, A234R, and L232M mutants, with no cleavage
at either the R or the M site, demonstrating that a methionine
residue at P3 of the R or M site abolishes recognition by the
full-length protease (Fig. 2). Furthermore, these data con-
firmed that R site cleavage was required for M site cleavage, as
no 72-kDa product was observed.
Interestingly, these sequential cleavages seem to occur in the
order opposite those in other herpesviruses (5, 7, 19). How-
ever, in good agreement with observations for the cytomega-
lovirus protease (20) the full-length protease seemed to have
only weak activity, and the lack of cleavage at the M site when
the R site was not cleavable may be due to a combination of
the weak activity of the polyprotein and poor recognition of the
atypical MDV M site by the full-length protease.
As the MDV M site seemed to be cleaved only in trans by the
processed short protease, sequential cleavage seems to be nec-
essary, according to the model proposed for Epstein-Barr vi-
rus, with three steps and an inactive full-length protease acti-
vated by an unknown factor, involving the release of the active
short protease (2). Our results also expand the previously de-
scribed herpesvirus consensus cleavage site from (V, L, I)-X-
A/S to (V, L, I, M)-X-A/S.
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